|
HANAFUSA, Norio
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Associate Professor |
|
| Article types | Review article |
| Language | English |
| Peer review | Peer reviewed |
| Presence of invitation | Invited paper |
| Title | CART: Cell-free and Concentrated Ascites Reinfusion Therapy against malignancy-related ascites. |
| Journal | Formal name：Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Abbreviation：Transfus Apher Sci ISSN code：(1473-0502)1473-0502(Linking) |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 56(5),pp.703-707 |
| Author and coauthor | Ito Tetsuya, Hanafusa Norio |
| Authorship | Last author |
| Publication date | 2017/10 |
| Summary | A standard strategy against ascites, a common symptom observed in cirrhotic and cancer patients, includes restriction of sodium intake and use of a diuretic. Paracentesis is a widely applied method against refractory ascites that do not react to such treatment. However, emerging fatigue and hemodynamic instability are possibly attributable to a loss of protein included in ascites. Cell-free and Concentrated Ascites Reinfusion Therapy (CART) is also applied against refractory ascites. CART comprises three processes. After ascites is first filtered to remove cell components, it is concentrated to reduce its volume. Fluid obtained through these processes, including useful proteins such as albumin and globulin, is finally reinfused intravenously. CART was reported first in the 1970s. Since then, it has been applied mainly against cirrhotic ascites with a thinner cell component. Now, its indication is expanding to include malignancy-related ascites. Additionally, CART can be applied safely against malignancy-related ascites. Its favorable effects on control of patients' symptoms are anticipated, especially on fatigue. Although related evidence has not been established, CART can be anticipated for use as a strategy against refractory ascites. |
| DOI | 10.1016/j.transci.2017.08.018 |
| PMID | 28916401 |